Physician

Fauzia Paracha, MD

According to 2025 Medicare claims, Fauzia Paracha, MD (NPI: 1174639751) practices hematology/oncology in the Kiryas Joel-Poughkeepsie-Newburgh, NY market, with the plurality of this provider's patient population coming from Orange, NY. This provider's primary affiliated billing organization is COMPREHENSIVE BLOOD &CANCER MEDICAL CARE,PC (NPI: 1275868150; TIN: 271025838) and primary practice location at 12550-6528. Paracha is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Paracha's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 282 traditional Medicare patients, billed 96,926 HCPCS/CPT codes, and received $983,655 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,035 prescription claims across 160 beneficiaries totaling $2,771,288 in drug costs, led by Kyprolis (Carfilzomib). DME data shows 34 claims. Open Payments data shows 92 records totaling $2,108. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $992,142 to $2,771,288. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	255	84,856	$722,784
2016	281	94,358	$689,450
2017	344	121,208	$1,235,385
2018	375	124,967	$1,047,632
2019	389	176,106	$964,964
2020	361	168,359	$973,531
2021	401	105,134	$994,974
2022	403	171,495	$871,764
2023	353	212,961	$730,427
2024	282	96,926	$983,655

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	118	927	$992,142
2016	115	977	$1,517,661
2017	117	847	$1,430,784
2018	135	1,005	$2,268,867
2019	135	1,009	$1,533,911
2020	127	959	$2,534,181
2021	150	979	$1,718,551
2022	155	940	$1,876,496
2023	169	945	$1,760,565
2024	160	1,035	$2,771,288

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	36	$3,896
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	46	$2,284
2021	N/R	35	$36,084
2022	N/R	16	$50,976
2023	N/R	N/R	N/R
2024	N/R	34	$1,288

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	189	910	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	103	436	$66
96372	Injection of drug or substance under skin or into muscle	85	597	$11
36415	Insertion of needle into vein for collection of blood sample	215	1,310	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	112	721	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kyprolis	Carfilzomib	11	308	$368,178
Keytruda	Pembrolizumab	22	534	$337,024
Imfinzi	Durvalumab	21	588	$256,030
Lanreotide Acetate	Lanreotide Acetate	29	812	$247,359
Lenalidomide	Lenalidomide	18	504	$235,392

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	11	$550
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$513
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	92	$2,108	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Fauzia Paracha, MD?

Tedicare shows public-source Medicare data for Fauzia Paracha, MD (NPI 1174639751), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Fauzia Paracha, MD have ACO affiliation data?

Fauzia Paracha, MD is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Fauzia Paracha, MD?

Fauzia Paracha, MD is linked to COMPREHENSIVE BLOOD &CANCER MEDICAL CARE,PC (billing NPI 1275868150) in the available physician profile data.

Does Fauzia Paracha, MD have Open Payments data?

Fauzia Paracha, MD has 92 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.